Skip to Content
Merck
CN
  • Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis.

Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis.

Gut (2013-12-18)
P Ferenci, G Dusheiko
PMID24334256
MATERIALS
Product Number
Brand
Product Description
R9644
Sigma-Aldrich
Ribavirin, antiviral
Y0000377
Ribavirin, European Pharmacopoeia (EP) Reference Standard